ZA977326B - Tetrahydroquinoline derivatives - Google Patents

Tetrahydroquinoline derivatives

Info

Publication number
ZA977326B
ZA977326B ZA977326A ZA977326A ZA977326B ZA 977326 B ZA977326 B ZA 977326B ZA 977326 A ZA977326 A ZA 977326A ZA 977326 A ZA977326 A ZA 977326A ZA 977326 B ZA977326 B ZA 977326B
Authority
ZA
South Africa
Prior art keywords
tetrahydroquinoline derivatives
tetrahydroquinoline
derivatives
Prior art date
Application number
ZA977326A
Other languages
English (en)
Inventor
Romano Di-Fabio
Alessandra Pasquarello
Fabio Maria Sabbatini
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of ZA977326B publication Critical patent/ZA977326B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA977326A 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives ZA977326B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ZA977326B true ZA977326B (en) 1999-02-15

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA977326A ZA977326B (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives

Country Status (34)

Country Link
US (1) US6479488B1 (xx)
EP (1) EP0922034B1 (xx)
JP (1) JP4108129B2 (xx)
KR (1) KR100552864B1 (xx)
CN (1) CN1131214C (xx)
AP (1) AP877A (xx)
AR (1) AR008296A1 (xx)
AT (1) ATE221052T1 (xx)
AU (1) AU724473B2 (xx)
BR (1) BR9711311B1 (xx)
CA (1) CA2264118C (xx)
CO (1) CO4900066A1 (xx)
CZ (1) CZ296250B6 (xx)
DE (1) DE69714265T2 (xx)
DK (1) DK0922034T3 (xx)
EA (1) EA001704B1 (xx)
ES (1) ES2181030T3 (xx)
GB (1) GB9617305D0 (xx)
HU (1) HU225797B1 (xx)
ID (1) ID18095A (xx)
IL (1) IL128141A0 (xx)
IS (1) IS4953A (xx)
MY (1) MY116952A (xx)
NO (1) NO312241B1 (xx)
NZ (1) NZ333812A (xx)
PE (1) PE107098A1 (xx)
PL (1) PL194532B1 (xx)
PT (1) PT922034E (xx)
SI (1) SI0922034T1 (xx)
TR (1) TR199900336T2 (xx)
TW (1) TW449582B (xx)
WO (1) WO1998007704A1 (xx)
YU (1) YU6799A (xx)
ZA (1) ZA977326B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
WO2003057672A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
SI1696931T1 (sl) * 2003-12-22 2009-08-31 Acadia Pharm Inc Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
ES2531621T3 (es) 2005-07-22 2015-03-18 Mochida Pharmaceutical Co., Ltd. Derivado de heterociclidenacetamida novedoso
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
PL186781B1 (pl) * 1995-09-29 2004-02-27 Glaxo Wellcome Spa Nowy związek, pochodna tetrahydrochinoliny, sposób wytwarzania pochodnej tetrahydrochinoliny, środek farmaceutyczny i zastosowanie

Also Published As

Publication number Publication date
MY116952A (en) 2004-04-30
EA001704B1 (ru) 2001-06-25
PL194532B1 (pl) 2007-06-29
EA199900121A1 (ru) 1999-10-28
DE69714265D1 (de) 2002-08-29
CZ296250B6 (cs) 2006-02-15
NO312241B1 (no) 2002-04-15
IS4953A (is) 1999-01-22
TW449582B (en) 2001-08-11
NZ333812A (en) 2000-07-28
GB9617305D0 (en) 1996-09-25
US6479488B1 (en) 2002-11-12
ID18095A (id) 1998-02-26
CA2264118C (en) 2008-06-17
YU6799A (sh) 2000-03-21
AR008296A1 (es) 1999-12-29
ES2181030T3 (es) 2003-02-16
NO990723L (no) 1999-04-14
HU225797B1 (en) 2007-09-28
EP0922034A1 (en) 1999-06-16
EP0922034B1 (en) 2002-07-24
AP9901459A0 (en) 1999-03-31
DE69714265T2 (de) 2003-03-06
CO4900066A1 (es) 2000-03-27
BR9711311A (pt) 1999-08-17
PT922034E (pt) 2002-12-31
AU724473B2 (en) 2000-09-21
CA2264118A1 (en) 1998-02-26
KR100552864B1 (ko) 2006-02-20
JP2001508031A (ja) 2001-06-19
TR199900336T2 (xx) 1999-04-21
HUP9903108A3 (en) 2004-04-28
ATE221052T1 (de) 2002-08-15
WO1998007704A1 (en) 1998-02-26
SI0922034T1 (en) 2003-02-28
PE107098A1 (es) 1999-01-15
PL331562A1 (en) 1999-07-19
DK0922034T3 (da) 2002-11-18
JP4108129B2 (ja) 2008-06-25
NO990723D0 (no) 1999-02-16
CN1227544A (zh) 1999-09-01
AU4551897A (en) 1998-03-06
KR20000068172A (ko) 2000-11-25
CN1131214C (zh) 2003-12-17
BR9711311B1 (pt) 2009-01-13
AP877A (en) 2000-09-27
CZ52999A3 (cs) 1999-07-14
IL128141A0 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
IL113844A0 (en) Quinoline derivatives
IL125811A0 (en) 6-phenylpyridyl-2-amine derivatives
AP9701156A0 (en) 6-phenylpyridyl-2-amine derivatives
IL125379A (en) 19-nor-pregnene derivatives
ZA977326B (en) Tetrahydroquinoline derivatives
ZA974053B (en) Alkylaminobenzothiazole and -benzoxazole derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
GB9404378D0 (en) Quinoline derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
PL334558A1 (en) Cephalosporinic derivatives
ZA954269B (en) Quinoline derivatives
HU9701479D0 (en) N-benzylazolium derivatives
GB9402275D0 (en) Quinoline derivatives
GB9604996D0 (en) Benzodiazonine derivatives
GB9413150D0 (en) Quinoline derivatives
GB9600063D0 (en) Guaridine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
ZA971911B (en) 2-thioxo-tetrahydropyrimidin-4-one derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
IL126806A0 (en) Quinoline derivatives
GB9402306D0 (en) Quinoline derivatives
GB9413937D0 (en) Quinoline derivatives